Novartis will add a new North Carolina facility for active pharmaceutical ingredient (API) manufacturing for solid dosage ...

Manufacturing is no longer separate from software, and it never will be again. APIs have transformed factories into connected ...

Opportunities in the pharmaceutical API manufacturing market include leveraging rising demand for complex biologics, ...

Pharmaceutical Executive: What elements is the conversation about bringing pharma manufacturing home missing? Charlie Lyon: ...

The MarketWatch News Department was not involved in the creation of this content. The global industry was valued at US$ 38.9 Bn in 2022 and is expected to register a CAGR of 7.1% from 2023 to 2031.

The track by which API manufacturing processes are prepared for commercial use is comparable to overlapping integrative process evaluations at commercial scale. This ensures the process is ...

BEIJING--(BUSINESS WIRE)--Pharmaron Beijing Co., Limited (Stock Code: 300759.SZ/3759.HK) (“Pharmaron”) announced today that it has acquired Aesica Pharmaceuticals Limited (“The Cramlington Site”) from ...

The global industry was valued at US$ 38.9 Bn in 2022 and is expected to register a CAGR of 7.1% from 2023 to 2031. Demand for biologics, biosimilars, and other biopharmaceuticals is growing at a ...

India hosts more active pharmaceutical ingredient (API) manufacturing sites that are compliant with the U.S. Food and Drug Administration than any country outside the U.S., and it produces more ...

Pakistan’s pharmaceutical manufacturing industry is one of the country’s largest and fastest growing industries. It includes more than 650 manufacturers and accounts for approximately Rs. 748 billion ...